Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of total neoadjuvant therapy for locally advanced lower rectal cancer
jRCTs021230062Recruiting
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer. Primary endpoint: Incidence of adverse events during preoperative treatment. Started Feb 2024; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs021230062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021230062.